BriaCell’s Bria-OTS+™ Mechanism of Action Validated in Highly Rated Peer Reviewed Cancer Journal

Core Insights - BriaCell Therapeutics Corp. has published research on the mechanism of action of its next-generation personalized off-the-shelf immunotherapy, Bria-OTS+, in collaboration with the National Cancer Institute (NCI) [1][2][7] - The study highlights the anti-tumor effects of Bria-OTS+, demonstrating that semi-allogeneic dendritic-cell vaccines enhance CD4⁺ T-cell help and strengthen CD8⁺ T-cell responses against tumors [2][7] - The findings validate the design principle of Bria-OTS+, emphasizing the importance of partial HLA matching for effective tumor-antigen presentation and robust CD4⁺ helper responses [2][7] Company Overview - BriaCell is a clinical-stage biotechnology company focused on developing novel immunotherapies aimed at transforming cancer care [5] - The lead candidate, Bria-IMT, is currently being evaluated in a Phase 1/2a study for patients with metastatic recurrent breast cancer, which includes both monotherapy and combination therapy cohorts [4] Research Publication - The publication titled "Enhancing dendritic cell cancer vaccine by allogeneic MHC class II expression and Treg depletion" has been featured in JCI Insight, a peer-reviewed journal [2] - The research provides insights into the cellular immunotherapy platform technology of BriaCell, aligning with the encouraging clinical results reported in recent studies [2]